Twist Q3 FY2026: DNA Synthesis revenue $56.6M, up 39% YoY; AI drug discovery shows triple-digit growth

Twist Bioscience/Silicon DNA Synthesis

Twist reported Q3 FY2026 DNA Synthesis revenue of $56.6M, up 39% year-over-year. The company raised full-year FY2026 guidance to $194–199M (15–18% growth). AI-enabled drug discovery is a major growth driver, with five major customers and triple-digit growth rates.

• Q3 FY2026 DNA Synthesis revenue: $56.6M, up 39% YoY
• Full-year FY2026 guidance: $194–199M, 15–18% growth
• Five major AI drug discovery customers
• AI-enabled drug discovery growing at triple-digit rates
• Single largest purchase order to date